Shayla Love - Patents and psychedelics, past and future

Psychedelic patents present complex challenges regarding ownership and access within the emerging mental health industry. Patent systems frequently allow companies to claim ownership over fundamental therapy components or proprietary variations of existing substances, creating barriers that may hinder open research and restrict patient access. This dynamic reflects broader patterns in the biotechnology sector where patent strategies are used to secure monopolies and maximize returns. Moving forward, the psychedelic community is tasked with navigating these commercial pressures while promoting an innovation culture that prioritizes public interest. Alternative approaches, such as patent pools and strategic collaborations, offer potential pathways that could protect core research without stifling the development of more accessible treatment models. Establishing robust standards for novelty and transparency in patent examination is essential to prevent speculative filing practices from slowing scientific progress.